News BMS' Opdivo still streets ahead of Merck rival BMS to refocus operations, according to Q3 results.
News AZ halts recruitment on head and neck cancer trial FDA calls for hold after reports of bleeding.
Views & Analysis ESMO review: advances in immunotherapy, EMA dialogue and pa... QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
Partner Content Partner Content Giving drug candidates the greatest chance for success With the advent of new targeted treatments and immunotherapies, Quintiles has provided clinical services for over 700 phase 1 and phase 2 oncology studies since 2011.
Views & Analysis Immuno-oncology: how to keep ahead in a fast-moving field In the last two years, the first PD-1 checkpoint inhibitor drugs to reach patients have launched a revolution in cancer care.
Partner Content Partner Content VIDEO: Streamlining the process of patient enrollment Ever more-specific cancer medicines carry the advantage of more personalised treatments for those with the disease.
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
